Selective beta2-adrenoceptor agonist enhances sensitivity to cisplatin in non-small cell lung cancer cell line.

  • Authors:
    • T Bando
    • M Fujimura
    • K Kasahara
    • T Ueno
    • T Matsuda
  • View Affiliations

  • Published online on: January 1, 2000     https://doi.org/10.3892/or.7.1.49
  • Pages: 49-101
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cisplatin is a key drug in chemotherapy for lung cancer. It has been reported that intracellular accumulation of cisplatin is an important step as a determinant for resistance to cisplatin, which may be modulated by Na+, K+-ATPase activity. And it has been reported that isoproterenol, a beta-adrenoceptor agonist, enhances sensitivity to cisplatin in non-small cell lung cancer (NSCLC) cell lines. In this study, the effects of the selective beta1, beta2, and beta3-adrenoceptor agonists on membrane Na+, K+-ATPase activity and sensitivity to cisplatin were evaluated using human non-small cell lung cancer cell line. In the NSCLC cell line, sensitivity to cisplatin was improved by treatment with procaterol, a selective beta2-adrenoceptor agonist. Na+, K+-ATPase was activated and intracellular accumulation of cisplatin increased with the treatment. However, beta1 or beta3-adrenoceptor agonist did not modulate sensitivity to cisplatin or Na+, K+-ATPase activity. These results suggest that beta2-adrenoceptor may be one of the determinants for sensitivity to cisplatin in NSCLC. Exogenous beta2-adrenoceptor agonists may improve the antitumor effect of chemotherapy involving cisplatin.

Related Articles

Journal Cover

Jan-Feb 2000
Volume 7 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Bando T, Fujimura M, Kasahara K, Ueno T and Matsuda T: Selective beta2-adrenoceptor agonist enhances sensitivity to cisplatin in non-small cell lung cancer cell line.. Oncol Rep 7: 49-101, 2000
APA
Bando, T., Fujimura, M., Kasahara, K., Ueno, T., & Matsuda, T. (2000). Selective beta2-adrenoceptor agonist enhances sensitivity to cisplatin in non-small cell lung cancer cell line.. Oncology Reports, 7, 49-101. https://doi.org/10.3892/or.7.1.49
MLA
Bando, T., Fujimura, M., Kasahara, K., Ueno, T., Matsuda, T."Selective beta2-adrenoceptor agonist enhances sensitivity to cisplatin in non-small cell lung cancer cell line.". Oncology Reports 7.1 (2000): 49-101.
Chicago
Bando, T., Fujimura, M., Kasahara, K., Ueno, T., Matsuda, T."Selective beta2-adrenoceptor agonist enhances sensitivity to cisplatin in non-small cell lung cancer cell line.". Oncology Reports 7, no. 1 (2000): 49-101. https://doi.org/10.3892/or.7.1.49